Publication
Peer-Reviewed
Evidence-Based Oncology
February 2021Volume27 Issue 2
Supplemental Material: Cost of Home vs Clinic Administration of Paclitaxel in Metastatic Breast Cancer
Author(s):
Home administration of oral paclitaxel and encequidar is associated with potential cost savings for payers compared with clinic administration of intravenous chemotherapy in metastatic breast cancer patients.
Articles in this issue
Use of COTA Nodal Address Highlights Variance in Cancer Care Cost: An Interview With Donald M. Berwick, MD, MPP
Radiation Oncology’s Role in the Next Chapter of Payment Reform
ACCC and ASCO Collaborative Targets Disparities in Cancer Clinical Trials
Flying the Plane While You Build It
The Untapped Potential of Cell and Gene Therapy
Interview: Tanya Siddiqi, MD, Discusses the Promise of Reduced Toxicity With Liso-Cel
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Related Videos
Related Content
